Daxor reports new studies using Blood Volume Analysis technology

Daxor (DXR) announces new studies from Duke University Medical Center and Yale School of Medicine, presented at the Technology and Heart Failure Therapeutics Conference, or THT. Held from February 11-13, at the Omni Boston Hotel at the Seaport, the event gathered leading experts in heart failure innovation. The studies provide critical insights using Daxor’s Blood Volume Analysis, or BVA, technology, highlighting the superior accuracy for fluid measurement by BVA compared to the limited accuracy of pulmonary artery pressure monitoring, while also unveiling new findings on diuretic therapy and its implications for enhanced treatment outcomes. Key points include: No correlation between pulmonary artery pressure readings and actual blood volume as measured by BVA, illustrating the benefit of BVA for HF volume care; Challenges industry assumptions about pressure monitoring as a useful proxy for volume; Suggests current monitoring methods may miss critical patient information; A 5-year study using BVA examined the diuretic mechanism of action, showing the accuracy of BVA to detect shifts in volume as the gold standard; Revealed new insights into fluid removal process; Potential to improve treatment for millions on diuretic therapy.